Paderu R. Kirkpatrick icaac 2012 finalprogram web4a

98 SCIENTIFIC SESSIONS September 9-12 | E-807 Susceptibilities of Clostridium difficile to CB-183,315 and Comparators L. Chesnel 1 , A. E. Crist, Jr 2 , R. M. Patti, JD 2 , D. R. Snydman 3 , J. Kishel 1 ; 1 Cubist Pharmaceuticals, Lexington, MA, 2 York Hosp., York, PA, 3 Tufts Med. Ctr., Boston, MA. E-808 In Vitro Activity of Cadazolid against 209 Toxigenic Isolates of Clostridium difficile

D. W. Hecht

1,2 , D. N. Gerding 1,2 , J. R. Osmolski 1 , S. Sambol 1 , A. Cheknis, BA 2 ; 1 Loyola Univ. Med. Ctr., Maywood, IL, 2 Hines Veterans Admin. Hosp., Hines, IL. ------------------------------------------------------------------------ 096 F Poster Session New Antifungal Agents Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-809 Antifungal Activities of a Novel Arylamidine T-2307 against Azole-Resistant Aspergillus Species, A. calidoustus K. Yamashita, E. Yamada, M. Kaeriyama, H. Nishikawa, N. Fujino, N. No- mura, J. Mitsuyama; Res. Lab., Toyama Chemical Co.,Ltd., Toyama, Japan. F-810 Antifungal Spectrum, In Vivo Efficacy and Structure Activity Relationship of Ilicicolin H S. Singh, W. Liu, X. Li, T. Chen, A. Shafiee, D. Card, G. Abruzzo, A. Flattery, C. Gill, J. Thompson, M. Rosenbach, S. Dreikorn, V. Hornak, M. Meinz, R. Kelly, J. Onishi; Merck Co., Inc., Rahway, NJ. F-811 Comparative In Vitro Activities of Fluconazole, Voriconazole, and MXP-4509 against 256 Candida Isolates from Romanian Tertiary Hospitals

M. Mares

1 , V. Nastasa 1 , R. Moraru 1 , B. Minea 2 , L. Miron 1 ; 1 Ion Ionescu de la Brad Univ., IASI, Romania, 2 Petru Poni Inst. of Macromolecular Chemistry, IASI, Romania. F-812 Sulphur Containing Acetamide, from an Endophytic Fungus Emericella sp. Isolated From Azadirachta indica

S. Mittal

1,2 , S. Kumar 1 , S. Gowil 1 , D. Shrivastava 1 ; 1 Jaipur Natl Univ, Jaipur, India, 2 Amol Pharmaceuticals Pvt. Ltd., Jaipur, India. F-813 Biochemical Evaluation of Rtt109 Inhibitor as a Potential Anti-Fungal Agent J. Pupaibool, T. J. Kottom, A. H. Limper; Mayo Clinic, Rochester, MN. F-814 Milbemycins: Not Just Fungal ABC-Transporter Inhibitors Withdrawn F-815 Antifungal Properties of 2-Adamantanamine, a Potentiator of Azole Antifungals

M. LaFleur

1,2 , L. Long 3 , M. Ghannoum 3 , J. North 4 , R. Lee 4 , K. Lewis 2 ; 1 Arietis Corp., Boston, MA, 2 Northeastern Univ., Boston, MA, 3 Case Western Reserve Univ., Cleveland, OH, 4 St. Jude Children’s Res. Hosp., Memphis, TN. F-816 Potent Fungicidal Activity of Bis-Amidine Antibiotics T. J. Opperman, S. M. Kwasny, S. Nguyen, J. D. Williams, N. P. Peet, T. L. Bowlin; Microbiotix, Inc., Worcester, MA. F-817 ASP9726, A Unique 2nd Generation Echinocandin 1, Discovery of a Novel In Vitro Marker Correlated with In Vivo Anti-Aspergillus Efficacy T. Nakai, S. Matsumoto, S. Uchida, S. Takeda, S. Akamatsu, K. Maki; Astellas Pharma Inc., Tsukuba, Japan. F-818 ASP9726, A Unique 2nd Generation Echinocandin 2 - Synthesis and In Vitro Activity H. Morikawa, A. Okada, M. Tomishima, N. Kayakiri, D. Barrett, S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan. F-819 ASP9726, A Unique 2nd Generation Echinocandin 3 - In Vitro and In Vivo Activity against Aspergillus spp. S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki, A. Okada, N. Kayakiri, D. Barret; Astellas Pharma Inc.,, Tsukuba, Ibaraki, Japan. F-820 ASP9726, A Unique 2nd Generation Echinocandin 4 - In Vitro and In Vivo Activity against Candida spp. S. Akamatsu, S. Matsumoto, S. Uchida, T. Nakai, S. Takeda, K. Maki, H. Morikawa, M. Tomishima, D. Barrett; Astellas Pharma Inc.,, Tsukuba, Ibaraki, Japan. F-821 ASP9726, a Unique 2nd Generation Echinocandin 5 -In Vitro and In Vivo Activity of Combination Therapy with Voricon- azole against Aspergillus fumigatus S. Akamatsu, S. Matsumoto, S. Uchida, BS , T. Nakai, S. Takeda, K. Maki; Astellas Pharma Inc., Tsukuba, Ibaraki, Japan. F-822 Evaluation of ASP9726 on Glucan Synthase Inhibition from Echinocandin Susceptible and Resistant Fungi

P. Paderu

1 , C. Jiménez-Ortigosa 1 , S. Akamatsu 2 , S. Matsumoto 2 , D. Perlin 1 ; 1 Publ. Hlth. Res. Inst, Newark, NJ, 2 Astellas Pharma Inc., Ibaraki, Japan. F-823 Efficacy and Pharmacokinetics of ASP9726 in a Guinea Pig Model of Invasive Pulmonary Aspergillosis IPA

W. R. Kirkpatrick

1,2 , N. P. Wiederhold 3,1 , L. K. Najvar 1,2 , S. Matsumoto 4 , R. A. Bocanegra 1,2 , T. F. Patterson 1,2 ; 1 UTHSCSA, San Antonio, TX, 2 STVHCS, San Antonio, TX, 3 Univ. of Texas, Austin, TX, 4 Astellas, Tsubuka, Japan. Late-breaker presentations are listed behind the Late-breaker tab of the Final Program. ------------------------------------------------------------------------ 097 F Poster Session New Antiviral Agents Monday, 11:15 a.m.–1:15 p.m. . . . . . . . . . . . . . . . . . . . Halls A-C Presentations: F-824 Discovery of a Novel Antiviral against HSV-1 HSV-2 N. Kapoor 1 , R. Bhowmick 1 , H. Sivaramakrishnn 1 , S. Sharma 1 , B. M. Thomas 2 ; 1 Piramal Life Sci. Limited, Mumbai, India, 2 Piramal Healthcare Limited, Mumbai, India. F-825 New, Safe, Effective and Convenient Virucidal Agents Using Amino Acid K. Tsujimoto 1 , K. Ikeda 2 , Y. Suzuki 2 , H. Yamasaki. 3 , M. Nishide 1 , M. Yo- shida 1 , T. Arakawa 4 , A. H. Koyama 1,3 ; 1 Shin-ai Women’s Jr. Coll., Wakaya- ma, Japan, 2 Wakayama Med. Univ. Sch. Hlth. Nursing Sci., Wakayama, Japan, 3 Wakayama Med. Univ. Grad. Sch. Med., Wakayama, Japan, 4 Alliance Protein Lab., Thousand Oaks, CA. 99 MONDAY SCIENTIFIC SESSIONS Final Program F-826 Identification and Analysis of Hepatitis C virus NS3 Helicase Inhibitors Using a Nucleic Acid Binding Assay S. Mukherjee, A. M. Hanson, J. Ndjomou, D. Bartczak, L. A. Arnold, and D. N. Frick; Univ. of Wisconsin, Milwaukee, WI. F-827 Identification of Novel Small Molecule Inhibitors against the NS34A Serine Protease of Hepatitis C Virus by High-Through- put Screening H. Lee, T. Zhu, Y. Zhang, K. Patel, L. Truong, A. Sarkar, H. Jeong, M. E. Johnson; Univ. of Illinois, Chicago, IL. F-828 Discovery of a New Series of Pan-Genotypic NS5b Inhibitors for Hepatitis C: The Indazole Amide Class of Site IV Polymerase Antivirals

A. G. Draffan